Skip to main content
Transactions of the American Ophthalmological Society logoLink to Transactions of the American Ophthalmological Society
. 2002;100:215–224.

Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma.

Allan J Flach 1
PMCID: PMC1358964  PMID: 12545695

Abstract

PURPOSE: Evidence exists that the administration of cannabinoid derivatives can lower intraocular pressure. Some patients with glaucoma believe they are being deprived of a potentially beneficial treatment. Therefore, the Research Advisory Panel of California instituted the Cannabis Therapeutic Research Program to permit compassionate access to cannabinoid derivatives. Data about the potential therapeutic usefulness and toxicity of these agents were collected. This study reviews the results of this program with the specific aim of providing further direction for these investigational efforts. METHODS: A survey of local ophthalmologists indicated an impressive interest in participating in and contributing patients with glaucoma unresponsive to treatment to this study. Appropriate patients were treated with either orally administered delta-9-tetrahydrocannabinol capsules or inhaled marijuana in addition to their existing therapeutic regimen. RESULTS: Although 20 ophthalmologists were approved as investigators, only nine patients were enrolled in the study. An initial decrease in intraocular pressure was observed in all patients, and the investigator's therapeutic goal was met in four of the nine patients. However, the decreases in intraocular pressure were not sustained, and all patients elected to discontinue treatment within 1 to 9 months for various reasons. CONCLUSIONS: This uncontrolled, unmasked, nonrandomized study does not permit definitive conclusions about the efficacy or toxicity of cannabinoids in the treatment of glaucoma. There is an impression that this treatment can lower intraocular pressure, but the development of tolerance and significant systemic toxicity appears to limit the usefulness of this potential treatment. Both patients and ophthalmologists greatly appreciated the opportunity to participate in this study.

Full Text

The Full Text of this article is available as a PDF (40.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beilin M., Neumann R., Belkin M., Green K., Bar-Ilan A. Pharmacology of the intraocular pressure (IOP) lowering effect of systemic dexanabinol (HU-211), a non-psychotropic cannabinoid. J Ocul Pharmacol Ther. 2000 Jun;16(3):217–230. doi: 10.1089/jop.2000.16.217. [DOI] [PubMed] [Google Scholar]
  2. Benowitz N. L., Rosenberg J., Rogers W., Bachman J., Jones R. T. Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms. Clin Pharmacol Ther. 1979 Apr;25(4):440–446. doi: 10.1002/cpt1979254440. [DOI] [PubMed] [Google Scholar]
  3. Buchwald A., Browne C. E., Wu W. M., Ji F., Bodor N. Soft cannabinoid analogues as potential anti-glaucoma agents. Pharmazie. 2000 Mar;55(3):196–201. [PubMed] [Google Scholar]
  4. Crawford W. J., Merritt J. C. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm. 1979 May;17(5):191–196. [PubMed] [Google Scholar]
  5. Devane W. A., Dysarz F. A., 3rd, Johnson M. R., Melvin L. S., Howlett A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988 Nov;34(5):605–613. [PubMed] [Google Scholar]
  6. Devane W. A., Hanus L., Breuer A., Pertwee R. G., Stevenson L. A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992 Dec 18;258(5090):1946–1949. doi: 10.1126/science.1470919. [DOI] [PubMed] [Google Scholar]
  7. Drew W. G., Miller L. L. Cannabis: neural mechanisms and behavior--a theoretical review. Pharmacology. 1974;11(1):12–32. doi: 10.1159/000136463. [DOI] [PubMed] [Google Scholar]
  8. Hepler R. S., Frank I. M., Ungerleider J. T. Pupillary constriction after marijuana smoking. Am J Ophthalmol. 1972 Dec;74(6):1185–1190. doi: 10.1016/0002-9394(72)90741-6. [DOI] [PubMed] [Google Scholar]
  9. Hepler R. S., Frank I. R. Marihuana smoking and intraocular pressure. JAMA. 1971 Sep 6;217(10):1392–1392. [PubMed] [Google Scholar]
  10. Hollister L. E., Gillespie H. K. Delta-8- and delta-9-tetrahydrocannabinol comparison in man by oral and intravenous administration. Clin Pharmacol Ther. 1973 May-Jun;14(3):353–357. doi: 10.1002/cpt1973143353. [DOI] [PubMed] [Google Scholar]
  11. Hollister L. E. Structure-activity relationships in man of cannabis constituents, and homologs and metabolites of delta9-tetrahydrocannabinol. Pharmacology. 1974;11(1):3–11. doi: 10.1159/000136462. [DOI] [PubMed] [Google Scholar]
  12. Laine Krista, Järvinen Kristiina, Pate David W., Urtti Arto, Järvinen Tomi. Effect of the enzyme inhibitor, phenylmethylsulfonyl fluoride, on the IOP profiles of topical anandamides. Invest Ophthalmol Vis Sci. 2002 Feb;43(2):393–397. [PubMed] [Google Scholar]
  13. Lockhart A. B., West M. E., Lowe H. I. The potential use of Cannabis sativa in ophthalmology. West Indian Med J. 1977 Jun;26(2):66–70. [PubMed] [Google Scholar]
  14. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., Bonner T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990 Aug 9;346(6284):561–564. doi: 10.1038/346561a0. [DOI] [PubMed] [Google Scholar]
  15. Merritt J. C., Crawford W. J., Alexander P. C., Anduze A. L., Gelbart S. S. Effect of marihuana on intraocular and blood pressure in glaucoma. Ophthalmology. 1980 Mar;87(3):222–228. doi: 10.1016/s0161-6420(80)35258-5. [DOI] [PubMed] [Google Scholar]
  16. Merritt J. C., Perry D. D., Russell D. N., Jones B. F. Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. J Clin Pharmacol. 1981 Aug-Sep;21(8-9):467S–471S. doi: 10.1002/j.1552-4604.1981.tb02626.x. [DOI] [PubMed] [Google Scholar]
  17. Munro S., Thomas K. L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993 Sep 2;365(6441):61–65. doi: 10.1038/365061a0. [DOI] [PubMed] [Google Scholar]
  18. Pars H. G. The other side of marihuana research. Anesthesiology. 1973 Jun;38(6):519–520. doi: 10.1097/00000542-197306000-00001. [DOI] [PubMed] [Google Scholar]
  19. Pate D. W., Järvinen K., Urtti A., Jarho P., Järvinen T. Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. Curr Eye Res. 1995 Sep;14(9):791–797. doi: 10.3109/02713689508995801. [DOI] [PubMed] [Google Scholar]
  20. Purnell W. D., Gregg J. M. Delta(9)-tetrahydrocannabinol,, euphoria and intraocular pressure in man. Ann Ophthalmol. 1975 Jul;7(7):921–923. [PubMed] [Google Scholar]
  21. Straiker A. J., Maguire G., Mackie K., Lindsey J. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci. 1999 Sep;40(10):2442–2448. [PubMed] [Google Scholar]
  22. Turner C. E., Elsohly M. A., Boeren E. G. Constituents of Cannabis sativa L. XVII. A review of the natural constituents. J Nat Prod. 1980 Mar-Apr;43(2):169–234. doi: 10.1021/np50008a001. [DOI] [PubMed] [Google Scholar]
  23. Valk L. E. Proceedings: Hemp in connection with ophthalmology. Ophthalmologica. 1973;167(5):413–421. doi: 10.1159/000306985. [DOI] [PubMed] [Google Scholar]
  24. Valk L. E. Proceedings: Hemp in connection with ophthalmology. Ophthalmologica. 1973;167(5):413–421. doi: 10.1159/000306985. [DOI] [PubMed] [Google Scholar]

Articles from Transactions of the American Ophthalmological Society are provided here courtesy of American Ophthalmological Society

RESOURCES